The impact of pathogen‐reduced platelets in acute leukaemia treatment on the total blood product requirement: a subgroup analysis of an EFFIPAP randomised trial
Objective To evaluate the impact of pathogen‐reduced (PR) platelet transfusions on blood products requirement for clinical practice. Background PR platelets are increasing in use as standard blood products. However, few randomised trials have evaluated their impact on bleeding control or prevention....
Gespeichert in:
| Veröffentlicht in: | Transfusion medicine (Oxford, England) England), 2022-04, Vol.32 (2), p.175-177 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 177 |
|---|---|
| container_issue | 2 |
| container_start_page | 175 |
| container_title | Transfusion medicine (Oxford, England) |
| container_volume | 32 |
| creator | Garban, Frédéric Vilotitch, Antoine Tiberghien, Pierre Bosson, Jean Luc |
| description | Objective
To evaluate the impact of pathogen‐reduced (PR) platelet transfusions on blood products requirement for clinical practice.
Background
PR platelets are increasing in use as standard blood products. However, few randomised trials have evaluated their impact on bleeding control or prevention. Furthermore, PR platelets recirculate less than untreated platelets.
Methods
A subgroup study of the randomised clinical trial EFFIPAP compared three arms of platelet preparations (PR: P‐PRP/PAS, additive solution: P‐PAS and plasma P‐P arms respectively). The subgroup of acute leukaemia patients, in their chemotherapy induction phase, included 392 patients (133 P‐PRP/PAS arm, 132 P‐PAS arm and 130 P‐P arm). Blood requirements were analysed across over periods of 7 days.
Results
The number of platelet transfusions per week was significantly higher in the P‐PRP/PAS group 2.3 [1.6–3.3] compared to the control groups 1.9 [1.3–2.8] and 2.0 [1.3–3.0] for P‐P and P‐PAS groups respectively (p |
| doi_str_mv | 10.1111/tme.12848 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_03781725v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2619216124</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3598-af9ad015473229105602b3e053f69b42731cdf751296235ca6cac657b8d593453</originalsourceid><addsrcrecordid>eNp1kc1u1DAURi1ERYfCghdAXsIirX_iJGY3qmZopUHtYlhbN8lNJ-DEqe0UzY5H4Bl4NJ4ED1PKCm8sWeeez_ZHyBvOznlaF3HAcy6qvHpGFlwWKpM8r56TBdOqykpVVqfkZQhfGONSaPGCnErFuOZlsSA_tzuk_TBBE6nr6ARx5-5w_PX9h8d2brClk4WIFmOg_UihmSNSi_NXwKEHGj1CSh_T8EhjUkUXwdLaOpcmvUuKSD3ez73HA_aBAg1zfefdPFEYwe5DHw7BMNLVen19u7ylHsbWDX1I2dH3YF-Rkw5swNeP-xn5vF5tL6-yzc3H68vlJmuk0lUGnYaWcZWXUgjNmSqYqCUyJbtC17koJW_arlRc6EJI1UDRQFOosq5apWWu5Bl5f_TuwJrJ9wP4vXHQm6vlxhzOmCwrXgr1wBP77simN97PGKJJF27QWhjRzcGIgmvBCy7yf9rGuxA8dk9uzsyhPpM-0PypL7FvH7VzPWD7RP7tKwEXR-Bbb3H_f5PZflodlb8Bzqel0A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2619216124</pqid></control><display><type>article</type><title>The impact of pathogen‐reduced platelets in acute leukaemia treatment on the total blood product requirement: a subgroup analysis of an EFFIPAP randomised trial</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Garban, Frédéric ; Vilotitch, Antoine ; Tiberghien, Pierre ; Bosson, Jean Luc</creator><creatorcontrib>Garban, Frédéric ; Vilotitch, Antoine ; Tiberghien, Pierre ; Bosson, Jean Luc ; EFFIPAP Study Group ; for the EFFIPAP Study Group</creatorcontrib><description>Objective
To evaluate the impact of pathogen‐reduced (PR) platelet transfusions on blood products requirement for clinical practice.
Background
PR platelets are increasing in use as standard blood products. However, few randomised trials have evaluated their impact on bleeding control or prevention. Furthermore, PR platelets recirculate less than untreated platelets.
Methods
A subgroup study of the randomised clinical trial EFFIPAP compared three arms of platelet preparations (PR: P‐PRP/PAS, additive solution: P‐PAS and plasma P‐P arms respectively). The subgroup of acute leukaemia patients, in their chemotherapy induction phase, included 392 patients (133 P‐PRP/PAS arm, 132 P‐PAS arm and 130 P‐P arm). Blood requirements were analysed across over periods of 7 days.
Results
The number of platelet transfusions per week was significantly higher in the P‐PRP/PAS group 2.3 [1.6–3.3] compared to the control groups 1.9 [1.3–2.8] and 2.0 [1.3–3.0] for P‐P and P‐PAS groups respectively (p < 0.0001). However, the total number of platelets transfused per week was not different. The number of red blood cell concentrates (RBC) transfusion per week did not differ either.
Conclusion
In a homogeneous group of patients, platelet pathogen reduction resulted in an increased number of platelet units transfused per week while having no impact on the total number of platelets transfused or the number of RBC transfusion; resulting to an average requirement of 2 RBC and 2–3 platelets transfusions per week of marrow aplasia.</description><identifier>ISSN: 0958-7578</identifier><identifier>EISSN: 1365-3148</identifier><identifier>DOI: 10.1111/tme.12848</identifier><identifier>PMID: 35019176</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Blood Platelets ; Hemorrhage ; Humans ; Leukemia - therapy ; Life Sciences ; pathogen reduction ; Platelet Transfusion - adverse effects ; platelets transfusion ; randomised clinical trial ; Thrombocytopenia - therapy ; transfusion practice</subject><ispartof>Transfusion medicine (Oxford, England), 2022-04, Vol.32 (2), p.175-177</ispartof><rights>2022 British Blood Transfusion Society.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3598-af9ad015473229105602b3e053f69b42731cdf751296235ca6cac657b8d593453</citedby><cites>FETCH-LOGICAL-c3598-af9ad015473229105602b3e053f69b42731cdf751296235ca6cac657b8d593453</cites><orcidid>0000-0003-3981-0839</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Ftme.12848$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Ftme.12848$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35019176$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-03781725$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Garban, Frédéric</creatorcontrib><creatorcontrib>Vilotitch, Antoine</creatorcontrib><creatorcontrib>Tiberghien, Pierre</creatorcontrib><creatorcontrib>Bosson, Jean Luc</creatorcontrib><creatorcontrib>EFFIPAP Study Group</creatorcontrib><creatorcontrib>for the EFFIPAP Study Group</creatorcontrib><title>The impact of pathogen‐reduced platelets in acute leukaemia treatment on the total blood product requirement: a subgroup analysis of an EFFIPAP randomised trial</title><title>Transfusion medicine (Oxford, England)</title><addtitle>Transfus Med</addtitle><description>Objective
To evaluate the impact of pathogen‐reduced (PR) platelet transfusions on blood products requirement for clinical practice.
Background
PR platelets are increasing in use as standard blood products. However, few randomised trials have evaluated their impact on bleeding control or prevention. Furthermore, PR platelets recirculate less than untreated platelets.
Methods
A subgroup study of the randomised clinical trial EFFIPAP compared three arms of platelet preparations (PR: P‐PRP/PAS, additive solution: P‐PAS and plasma P‐P arms respectively). The subgroup of acute leukaemia patients, in their chemotherapy induction phase, included 392 patients (133 P‐PRP/PAS arm, 132 P‐PAS arm and 130 P‐P arm). Blood requirements were analysed across over periods of 7 days.
Results
The number of platelet transfusions per week was significantly higher in the P‐PRP/PAS group 2.3 [1.6–3.3] compared to the control groups 1.9 [1.3–2.8] and 2.0 [1.3–3.0] for P‐P and P‐PAS groups respectively (p < 0.0001). However, the total number of platelets transfused per week was not different. The number of red blood cell concentrates (RBC) transfusion per week did not differ either.
Conclusion
In a homogeneous group of patients, platelet pathogen reduction resulted in an increased number of platelet units transfused per week while having no impact on the total number of platelets transfused or the number of RBC transfusion; resulting to an average requirement of 2 RBC and 2–3 platelets transfusions per week of marrow aplasia.</description><subject>Blood Platelets</subject><subject>Hemorrhage</subject><subject>Humans</subject><subject>Leukemia - therapy</subject><subject>Life Sciences</subject><subject>pathogen reduction</subject><subject>Platelet Transfusion - adverse effects</subject><subject>platelets transfusion</subject><subject>randomised clinical trial</subject><subject>Thrombocytopenia - therapy</subject><subject>transfusion practice</subject><issn>0958-7578</issn><issn>1365-3148</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc1u1DAURi1ERYfCghdAXsIirX_iJGY3qmZopUHtYlhbN8lNJ-DEqe0UzY5H4Bl4NJ4ED1PKCm8sWeeez_ZHyBvOznlaF3HAcy6qvHpGFlwWKpM8r56TBdOqykpVVqfkZQhfGONSaPGCnErFuOZlsSA_tzuk_TBBE6nr6ARx5-5w_PX9h8d2brClk4WIFmOg_UihmSNSi_NXwKEHGj1CSh_T8EhjUkUXwdLaOpcmvUuKSD3ez73HA_aBAg1zfefdPFEYwe5DHw7BMNLVen19u7ylHsbWDX1I2dH3YF-Rkw5swNeP-xn5vF5tL6-yzc3H68vlJmuk0lUGnYaWcZWXUgjNmSqYqCUyJbtC17koJW_arlRc6EJI1UDRQFOosq5apWWu5Bl5f_TuwJrJ9wP4vXHQm6vlxhzOmCwrXgr1wBP77simN97PGKJJF27QWhjRzcGIgmvBCy7yf9rGuxA8dk9uzsyhPpM-0PypL7FvH7VzPWD7RP7tKwEXR-Bbb3H_f5PZflodlb8Bzqel0A</recordid><startdate>202204</startdate><enddate>202204</enddate><creator>Garban, Frédéric</creator><creator>Vilotitch, Antoine</creator><creator>Tiberghien, Pierre</creator><creator>Bosson, Jean Luc</creator><general>Blackwell Publishing Ltd</general><general>Wiley</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0003-3981-0839</orcidid></search><sort><creationdate>202204</creationdate><title>The impact of pathogen‐reduced platelets in acute leukaemia treatment on the total blood product requirement: a subgroup analysis of an EFFIPAP randomised trial</title><author>Garban, Frédéric ; Vilotitch, Antoine ; Tiberghien, Pierre ; Bosson, Jean Luc</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3598-af9ad015473229105602b3e053f69b42731cdf751296235ca6cac657b8d593453</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Blood Platelets</topic><topic>Hemorrhage</topic><topic>Humans</topic><topic>Leukemia - therapy</topic><topic>Life Sciences</topic><topic>pathogen reduction</topic><topic>Platelet Transfusion - adverse effects</topic><topic>platelets transfusion</topic><topic>randomised clinical trial</topic><topic>Thrombocytopenia - therapy</topic><topic>transfusion practice</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Garban, Frédéric</creatorcontrib><creatorcontrib>Vilotitch, Antoine</creatorcontrib><creatorcontrib>Tiberghien, Pierre</creatorcontrib><creatorcontrib>Bosson, Jean Luc</creatorcontrib><creatorcontrib>EFFIPAP Study Group</creatorcontrib><creatorcontrib>for the EFFIPAP Study Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Transfusion medicine (Oxford, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Garban, Frédéric</au><au>Vilotitch, Antoine</au><au>Tiberghien, Pierre</au><au>Bosson, Jean Luc</au><aucorp>EFFIPAP Study Group</aucorp><aucorp>for the EFFIPAP Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The impact of pathogen‐reduced platelets in acute leukaemia treatment on the total blood product requirement: a subgroup analysis of an EFFIPAP randomised trial</atitle><jtitle>Transfusion medicine (Oxford, England)</jtitle><addtitle>Transfus Med</addtitle><date>2022-04</date><risdate>2022</risdate><volume>32</volume><issue>2</issue><spage>175</spage><epage>177</epage><pages>175-177</pages><issn>0958-7578</issn><eissn>1365-3148</eissn><abstract>Objective
To evaluate the impact of pathogen‐reduced (PR) platelet transfusions on blood products requirement for clinical practice.
Background
PR platelets are increasing in use as standard blood products. However, few randomised trials have evaluated their impact on bleeding control or prevention. Furthermore, PR platelets recirculate less than untreated platelets.
Methods
A subgroup study of the randomised clinical trial EFFIPAP compared three arms of platelet preparations (PR: P‐PRP/PAS, additive solution: P‐PAS and plasma P‐P arms respectively). The subgroup of acute leukaemia patients, in their chemotherapy induction phase, included 392 patients (133 P‐PRP/PAS arm, 132 P‐PAS arm and 130 P‐P arm). Blood requirements were analysed across over periods of 7 days.
Results
The number of platelet transfusions per week was significantly higher in the P‐PRP/PAS group 2.3 [1.6–3.3] compared to the control groups 1.9 [1.3–2.8] and 2.0 [1.3–3.0] for P‐P and P‐PAS groups respectively (p < 0.0001). However, the total number of platelets transfused per week was not different. The number of red blood cell concentrates (RBC) transfusion per week did not differ either.
Conclusion
In a homogeneous group of patients, platelet pathogen reduction resulted in an increased number of platelet units transfused per week while having no impact on the total number of platelets transfused or the number of RBC transfusion; resulting to an average requirement of 2 RBC and 2–3 platelets transfusions per week of marrow aplasia.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>35019176</pmid><doi>10.1111/tme.12848</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0003-3981-0839</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0958-7578 |
| ispartof | Transfusion medicine (Oxford, England), 2022-04, Vol.32 (2), p.175-177 |
| issn | 0958-7578 1365-3148 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_03781725v1 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Blood Platelets Hemorrhage Humans Leukemia - therapy Life Sciences pathogen reduction Platelet Transfusion - adverse effects platelets transfusion randomised clinical trial Thrombocytopenia - therapy transfusion practice |
| title | The impact of pathogen‐reduced platelets in acute leukaemia treatment on the total blood product requirement: a subgroup analysis of an EFFIPAP randomised trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T16%3A38%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20impact%20of%20pathogen%E2%80%90reduced%20platelets%20in%20acute%20leukaemia%20treatment%20on%20the%20total%20blood%20product%20requirement:%20a%20subgroup%20analysis%20of%20an%20EFFIPAP%20randomised%20trial&rft.jtitle=Transfusion%20medicine%20(Oxford,%20England)&rft.au=Garban,%20Fr%C3%A9d%C3%A9ric&rft.aucorp=EFFIPAP%20Study%20Group&rft.date=2022-04&rft.volume=32&rft.issue=2&rft.spage=175&rft.epage=177&rft.pages=175-177&rft.issn=0958-7578&rft.eissn=1365-3148&rft_id=info:doi/10.1111/tme.12848&rft_dat=%3Cproquest_hal_p%3E2619216124%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2619216124&rft_id=info:pmid/35019176&rfr_iscdi=true |